Mizuho Securities analyst Difei Yang maintained a Buy rating on Viewray (VRAY) today and set a price target of $9.00. The company’s shares closed last Monday at $4.18.
According to TipRanks.com, Yang has currently no stars on a ranking scale of 0-5 stars, with an average return of -2.8% and a 38.6% success rate. Yang covers the Healthcare sector, focusing on stocks such as Audentes Therapeutics, Xeris Pharmaceuticals, and Revance Therapeutics.
Currently, the analyst consensus on Viewray is a Strong Buy with an average price target of $6.71, a 67.3% upside from current levels. In a report issued on December 3, Cantor Fitzgerald also maintained a Buy rating on the stock with a $6.00 price target.
See today’s analyst top recommended stocks >>
Based on Viewray’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $20.83 million. In comparison, last year the company had a GAAP net loss of $32.85 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ViewRay, Inc. engages in the design, manufacture and market magnetic resonance imaging (MRI) system. It develops MRIdian to address the key limitations of existing external-beam radiation therapy technologies, and employs MRI-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova on September 6, 2013 and is headquartered in Oakwood Village, OH.
